Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab)

Yukinori Nakagawa; Uichi Ikeda; Masahiro Hirose; Satoshi Ubukata; Taka-Aki Katsuki; Yuichiro Kaminishi; Tsutomu Saito; Mitsugu Hironaka; Tohru Izumi; Kazuyuki Shimada

doi:10.1253/circj.68.172

Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab)

Circ J. 2004 Feb;68(2):172-3. doi: 10.1253/circj.68.172.

Authors

Yukinori Nakagawa¹, Uichi Ikeda, Masahiro Hirose, Satoshi Ubukata, Taka-Aki Katsuki, Yuichiro Kaminishi, Tsutomu Saito, Mitsugu Hironaka, Tohru Izumi, Kazuyuki Shimada

Affiliation

¹ Division of Cardiovascular Medicine, Jichi Medical School, Tochigi, Japan.

PMID: 14745155
DOI: 10.1253/circj.68.172

Abstract

Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Gallium Radioisotopes
Heart Neoplasms / diagnosis
Heart Neoplasms / drug therapy*
Humans
Immunohistochemistry
Lymphoma, B-Cell / diagnosis
Lymphoma, B-Cell / drug therapy*
Male
Radionuclide Imaging
Remission Induction / methods
Rituximab
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Gallium Radioisotopes
Rituximab